Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Pfizer has launched its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific...

Piramal has agreed to sell its healthcare data and analytics unit, Decision Resources Group (DRG), to Clarivate Analytics for $950 million (includes $900 million on closing and $50 million to be received at the end of 12 months from the date of...

Merck & Co. has completed its previously announced $2.7-billion acquisition of ArQule, a biopharmaceutical company focused on the discovery and development of kinase inhibitors for treating cancer and other diseases. With the completion of the...

Astellas has completed its $3-billion acquisition of Audentes Therapeutics, a San Francisco, California-based adeno-associated virus (AAV) clinical-stage gene-therapy company that focuses on rare neuromuscular diseases. With the completion of the...

AbbVie, upon completing its $63-billion acquisition of Allergan, plans to create a new global business, Allergan Aesthetics, which will include Allergan’s Botox and related products. The new business will become effective upon the expected...

A roundup of developments and latest news from Germany (Bayer, WuXi Biologics), South Korea (Avacta, Daewoong), and US (Hikma, ANI Pharmaceuticals). Germany Bayer, WuXi Biologics in Acquisition Agreement for Bayer’s Drug-Product Mfg Plant Bayer...

California’s Governor Gavin Newsom has proposed a new CalRx generic-drug program in his 2020–21 State Budget proposal that he submitted to California’s State Legislature, which would make California the first state to create its own generic-drug...

The European Medicines Agency (EMA) and its European and international partners have launched a pilot program to increase their cooperation in the inspection of manufacturers of sterile medicines for human use. This new initiative is built on...